Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

s proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metastatic disease.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company that is developing groundbreaking endothelial cell-based therapies designed to regulate the body's natural healing and repair processes in various critical therapeutic areas. The company has initially focused on developing therapies to improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stent placements, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The company's lead program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 clinical trials. Pervasis is also applying its endothelial cell-based platform technology to develop an oncology therapy focused on preventing solid tumor growth, cancer recurrence and metastatic disease, as well as products for inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1)  Dixon et al. DAC Study Group. Effect of dipyridamole plus aspirin on he
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... STUDY OBJECTIVES The objective of ... an overview of the current and future characteristics ... key objective is to present a comprehensive analysis ... important tool in the treatment of various diseases. ... within the protein therapeutics market, which includes peptide ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the Asia ... China , India , ... rate through 2023. Dental implant procedure volumes will grow as physicians ... Other key findings from Decision Resources Group,s coverage of ... , Dental implant penetration: Penetration of dental implants among ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3
... TITUSVILLE, N.J., Aug. 21 The U.S. ... letter regarding the New Drug Application (NDA) for carisbamate, ... , , The NDA, filed in ... Development, L.L.C. (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. ...
... FORT LAUDERDALE, Fla., Aug. 20 OmniComm Systems, Inc. (OTC ... the EDC marketplace, today announced that Impax Pharmaceuticals, the brand ... TrialMaster EDC solution for conducting a Phase III study in ... clinical trial there can be significant challenges in getting trial ...
Cached Medicine Technology:FDA Issues Complete Response Letter for Carisbamate 2FDA Issues Complete Response Letter for Carisbamate 3Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease 3
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining ... vulnerable family members. , Life insurance plans provide important ... family should always carry a life insurance policy as ... of the family. , Clients can choose from ... temporary coverage or from a permanent policy. No medical ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... October 01, 2014 Scientists at the ... drugs that target immune system proteins has the power ... just posted details of the new study on their ... , Researchers in the UWA School of Pathology ... drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... October 01, 2014 Woodland Hills ... to a group of dental specialists who treat full ... Spain city of Oviedo. Dr. Reshad of the Anacapa ... with clients on two continents, will give a full-day ... full mouth reconstruction. , “These specialists want to improve ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... 13 Thomson Reuters announced,today that St. Peter,s Hospital ... -- such as increasing its discharge instruction,compliance for heart ... percent in first-quarter 2008., St. Peter,s Hospital, part ... of only 10 hospitals in the nation named for ...
... Utah, Oct. 13 Nutraceutical,International Corporation (Nasdaq: ... Cory McQueen, Vice President and Chief Financial Officer,are ... on Wednesday,October 15, 2008 at the Canaccord Adams ... scheduled for 2:30 PM Eastern,Time that day and ...
... the combination of low plasma levels of antioxidants and blue ... of the eye disease age-related macular degeneration (AMD), according to ... Ophthalmology , one of the JAMA/Archives journals. , ... the authors write as background information in the article. "While ...
... Oct. 13 Today,s autism research draws on ... magnetic,resonance imaging (fMRI) to neural development. At the ... in Autism," 16 of,the world,s most prominent autism ... disorder and discuss the direction of future,study that ...
... KEEP WARM THIS WINTER WITH THE VIPER RESPONDER LE SPECIAL ... EDITION VEHICLE SECURITY & REMOTE START SYSTEM, ... DEI Holdings Inc. (Nasdaq: DEIX ), has joined,the fight ... 2-Way Vehicle Security & Remote Start systems from Viper,supporting Susan ...
... interruption to shipments or service to new or ... Cardiac Science,Corporation (Nasdaq: CSCX ) announced today ... action of certain automated external,defibrillators (AEDs) manufactured between ... this time frame may have a component whose ...
Cached Medicine News:Health News:St. Peter's Hospital of Albany Improves Core Measures Processes 2Health News:St. Peter's Hospital of Albany Improves Core Measures Processes 3Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 2Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 3Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2Health News:Carnegie Mellon International Autism Symposium to Feature Groundbreaking Research, Oct. 17-18 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 3Health News:Cardiac Science Initiates Voluntary Field Corrective Action of Certain AEDs 2Health News:Cardiac Science Initiates Voluntary Field Corrective Action of Certain AEDs 3
Weight is evenly distributed by fully adjustable velcro straps that cross in the back. Adjustable back velcro keeps apron snug....
6" wide elastic belt transfers the apron weight off the shoulders to the hips making this apron the most comfortable for long procedures. Adjustable. Velcro keeps apron snug....
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... The NS272 is a fully featured ... is used to monitor neuromuscular blocks during ... nerve location during regional anesthesia. , ... are the only known PNS that can ...
Medicine Products: